Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

of the two available peginterferon regimens had been conducted to date. Cross-study comparisons and retrospective analyses of previous data are difficult to interpret because of differences in study designs, patient populations and assay limits.

Mark Sulkowski, M.D., and John McHutchison, M.D., are the co-principal investigators of the IDEAL study. They also are co-chairmen of the IDEAL Publication Committee, which also includes three independent expert members not associated with the study to provide an unbiased evaluation of the data. The Publication Committee was responsible for the preparation of the prespecified data analysis plan for the statistical analysis conducted for the primary publication of the study results.

About PEGINTRON

In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy.

Use with Ribavirin: Ribavirin may cause birth defects and/or death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of Tokyo ... next-generation sequencing (NGS) gene panels, for blood cancers  ... new test, indicate favorable prognosis for patients with bone ... sees potential for developing companion diagnostics to guide treatment ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... May 15, 2012 Reportlinker.com ... research report is available in ... Global ... Marketing Spend and Sales Strategies ...
... May 15, 2012  Reportlinker.com announces that ... available in its catalogue: ... China Market Analysis, Size, Trends And ... In 2009, the global Osteoporosis drug ...
Cached Medicine Technology:Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 2Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 3Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 4Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 5Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 6Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 7Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 8Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 9Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 10Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 11Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 12Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 13Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 14Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 15Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 16Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 17Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 18Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015) 2Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015) 3Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015) 4
(Date:7/26/2014)... “Healthy teeth are important, and having your teeth cleaned regularly ... Health Center of Snohomish County (CHC) in their article, “ ... integration of medical and dental care is the best way ... encourage regular cleanings and checkups not only with a family ... adults will find knowledgeable and friendly staff that ...
(Date:7/26/2014)... 26, 2014 Another DePuy Pinnacle hip lawsuit ... has been filed by Wright & Schulte LLC. This ... behalf of an Erie County, Ohio man who alleges that ... and groin since receiving his Pinnacle Hip implant in 2008. ... be forced to undergo a complex and risky revision surgery ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 As ... chocolate, the true vision of Xoçai ... through its exclusive and healthy chocolate products. One ... blend of cacao, açaí berries and blueberries, an ... exclusive high-antioxidant blend is utilized in all of ...
(Date:7/25/2014)... TX (PRWEB) July 26, 2014 ... Laser Scanning Confocal Microscope Industry” is a ... Laser Scanning Confocal Microscope market. The report ... including Laser Scanning Confocal Microscope definition, classification, ... industry overview. This research covers international market analysis, ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... Battlefield in War On Heroin (7/20), police in Salem, ... seriously crack down on the recent heroin epidemic that has ... article focuses on one heroin-related overdose case in which police ... in the victim's cell phone. By pretending to be the ...
Breaking Medicine News(10 mins):Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 5Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:Multiple States Crack Down on Heroin Epidemic 2
... has entered into a collaboration with the Indian Council of ... cervical cancer drug, Gardasil.// ,This is the first public-private ... trials will be conducted for a human pappiloma virus (HPV) ... been developed by Merck and will be tried on 30 ...
... outbreak of flu and it is presumed that this year it ... In Texas and Colorado the flu case increased greatly in number ... Georgia the State Health Department reports to the press that they've ... Centers for Disease Control and Prevention in Atlanta cautions the need ...
... adolescents and 8.5 million American adults are becoming overweight, ... Americans have been // getting less and less exercise ... ,However the new nationwide study of over 5,300 Americans ... researchers found a significant proportion of US teenagers and ...
... the right to fight for receiving the new breast cancer drug, ... breast cancer and wants to make sure that it does not ... its early stage has meant that the primary care trust is ... recourse for the same. Even Patricia Hewitt, the Health Secretary has ...
... In Canada questions have arisen about the best approach whether ... out to be that more people want public services offering ... the London’s public Queen Elizabeth Hospital is an example financial ... the US a study reveals that the health care provided ...
... beneficial effects of physical activities such as running, jogging on ... has now been found by neuroscientists from Germany that running ... boost of memory. // ,The study ... sessions per week followed by which they had to take ...
Cached Medicine News:Health News:Merck, ICMR to conduct joint trials on cervical cancer vaccine 2
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Avaulta™ BioSynthetic Mesh ... mesh coated in the ... absorbable, hydrophilic film of ... segments of the Avaulta™ ...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
... Pelvicol® Acellular Collagen Matrix delivers the ... exceptional strength, versatility, and durability in ... the effectiveness of site-specific defect repair ... sterile, biocompatible, crosslinked porcine dermal collagen ...
Medicine Products: